Sanofi-Aventis to pay more than $20 bil. for Genzyme
TEXT OF STORY
STEVE CHIOTAKIS: The French pharmaceutical giant Sanofi-Aventis will pay $20 billion for Genzyme, that’s an American biotech firm based in Massachusetts.
The BBC’s Jon Bithrey is in London. He has more on this mega-deal that’s sure to make some waves. Hi Jon.
JON BITHREY: Hello Steve.
CHIOTAKIS: Now why has this French firm picked up Genzyme? What do they want with Genzyme?
BITHREY: Well Sanofi-Aventis is France’s biggest drug maker and it’s been after Genzyme for a while. Largely because Sanofi doesn’t have many new drugs of its own in the pipeline and it’s facing competition from generic producers. Genzyme makes a lot of treatments for rare diseases. Its best selling drug Cerezyme treats liver and neurological problems. It’s also producing a new range of drugs for high cholesterol.
CHIOTAKIS: $20 billion, Jon, is a lot of money. Is this a good deal for Sanofi?
BITHREY: Well not as good as it would have liked. It launched a hostile bid last September for $18.5 billion. That failed and it’s had to up that to more than $20 billion to get the board to agree. But Genzyme did have some production glitches of its best selling drugs a couple of years back and that pulled down its value, making it more vulnerable to a takeover. But this is still the biggest deal in the drug industry since Merck bought Schering Plough in 2009.
CHIOTAKIS: The BBC’s Jon Bithrey in London. Jon thank you.
BITHREY: Thank you Steve.
Stories You Might Like
There’s a lot happening in the world. Through it all, Marketplace is here for you.
You rely on Marketplace to break down the world’s events and tell you how it affects you in a fact-based, approachable way. We rely on your financial support to keep making that possible.
Your donation today powers the independent journalism that you rely on. For just $5/month, you can help sustain Marketplace so we can keep reporting on the things that matter to you.
